A step closer to nationwide electronic health record –based chronic disease surveillance: characterizing asthma prevalence and emergency department utilization from 100 million patient records through a novel multisite collaboration

ConclusionsOur initiative demonstrates the potential of intravendor customer collaboration and highlights an organizational approach that complements other data aggregation efforts seeking to achieve nationwide EHR-based chronic disease surveillance.
Source: Journal of the American Medical Informatics Association - Category: Information Technology Source Type: research

Related Links:

Condition:   Moderate-to-severe Allergic Asthma Interventions:   Drug: Omalizumab;   Drug: Placebo Sponsor:   Genentech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study estimated healthcare costs and utilisation for patients with AR and asthma. Mean annual outpatient visits, pharmaceutical costs and inpatient hospitalisations were calculated for 2010 and 2014, with pharmaceutical and inpatient costs stratified by AIT use. AR and asthma patients had a 35% higher mean number of physician visits and up to 90% higher mean pharmaceutical costs compared to controls. The cost of pharmaceuticals and inpatient hospitalisations were 54% lower in those prescribed AIT. Further research is recommended to understand the reasons for these cost differences. PMID: 31818082 [PubMed - as supplied by publisher]
Source: European Annals of Allergy and Clinical Immunology - Category: Allergy & Immunology Tags: Eur Ann Allergy Clin Immunol Source Type: research
We report a case of serum sickness-like reaction in a patient treated with omalizumab for chronic idiopathic urticaria/angioedema. An adult female experienced episodic urticaria/angioedema without repeatable trigger, ultimately receiving diagnosis of chronic idiopathic urticaria/angioedema. After initial treatment, attempts with escalating cetirizine and montelukast doses were unsuccessful due to sedation; she began treatment with subcutaneous omalizumab 150 mg monthly. Urticaria frequency partially improved after two injections; therefore, the dose was increased to 300 mg after four treatments. Several days afte...
Source: Military Medicine - Category: International Medicine & Public Health Tags: Mil Med Source Type: research
Authors: Chen LC, Zeng GS, Wu LL, Zi M, Fang ZK, Fan HZ, Yu HP Abstract Objective: To evaluate the diagnostic value of fractional exhaled nitric oxide (FeNO) and maximum mid-expiratory flow (MMEF) for differentiating cough variant asthma (CVA) from chronic cough in patients with or without allergic rhinitis.Methods: In total, 328 patients with chronic cough who underwent spirometry and FeNO testing were consecutively included in the retrospective analysis. Patients were divided into the CVA (n = 125) or NCVA (n = 203) groups according to the diagnostic criteria of CVA. Receiver operating...
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
ConclusionsThe maritime monsoon climate creates an additional strain on both respiratory system and systems that ensure the peroxidation balance worsening bronchopulmonary pathology.
Source: Journal of Environmental Health Science and Engineering - Category: Environmental Health Source Type: research
Epidemiological studies report that overweight or obese asthmatic subjects have more severe disease than those of a healthy weight. We postulated that accumulation of adipose tissue within the airway wall may occur in overweight patients and contribute to airway pathology. Our aim was to determine the relationship between adipose tissue within the airway wall and body mass index (BMI) in individuals with and without asthma. Transverse airway sections were sampled in a stratified manner from post mortem lungs of control subjects (n=15) and cases of nonfatal (n=21) and fatal (n=16) asthma. The relationship between airway adi...
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: COPD and smoking, Asthma and allergy Original Articles: Asthma and COPD Source Type: research
By A. MARK FENDRICK, MD It’s great news to read headlines that the average health-insurance premium will drop by 4% next year in the 38 states using federal Obamacare exchanges. As millions of Americans entered open enrollment this year to choose their health insurance plans, it is important to remember that premiums are only one of the ways that we pay for our medical coverage.  In many plans lower premiums (paid by everyone) often mean a higher deductible — or paying more out-of-pocket before insurance coverage kicks in. This burden is paid only by those who use medical care services. Deductible...
Source: The Health Care Blog - Category: Consumer Health News Authors: Tags: Health Policy Value-Based Care Health insurance health insurance premiums Open Enrollment VBID Source Type: blogs
CONCLUSIONS: Both industrial- and traffic-related air pollution have a negative effect on asthma risk in young males. Studies evaluating the association between asthma risk and specific air pollutants (e.g., sulfur dioxide, particulate matter, and nitrogen dioxide) are needed to ascertain the effects of individual air pollutants on asthma occurrence. PMID: 31814340 [PubMed - in process]
Source: The Israel Medical Association Journal - Category: General Medicine Tags: Isr Med Assoc J Source Type: research
Publication date: Available online 11 December 2019Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Eleonora Di Salvo, Vincenzo Patella, Marco Casciaro, Sebastiano GangemiAbstractMontelukast the leukotriene receptor antagonist is an anti-inflammatory drug that causes bronchodilation and for this reason it is used to improve inflammatory states in asthma and allergic rhinitis. Montelukast is generally considered a safe drug with the occurrence of a few adverse drug reactions (ADRs) and anti-leucotrienes are usually well-tolerated by adults and young patients. Starting from these premises the purpose of this review...
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research
The editors and staff of the Annals of Allergy, Asthma and Immunology would like to thank the flowing individuals who gave of their time to provide reviews of submitted manuscripts between January 1 and June 30, 2019. The high-quality manuscript reviews provided by these individuals is essentially to the peer review process so necessary for a journal like ours to provide scientifically sound as well as interesting and engaging articles for our readers. Thanks to each of you for your service.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Source Type: research
More News: Asthma | Electronic Health Records (EHR) | Emergency Medicine | Epidemiology | Information Technology | Study | USA Health